243 related articles for article (PubMed ID: 34504010)
1. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
[TBL] [Abstract][Full Text] [Related]
2. Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics.
Licari G; Martin KP; Crames M; Mozdzierz J; Marlow MS; Karow-Zwick AR; Kumar S; Bauer J
Mol Pharm; 2023 Feb; 20(2):1096-1111. PubMed ID: 36573887
[TBL] [Abstract][Full Text] [Related]
3. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
4. Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies.
Jetha A; Thorsteinson N; Jmeian Y; Jeganathan A; Giblin P; Fransson J
MAbs; 2018; 10(6):890-900. PubMed ID: 30110240
[TBL] [Abstract][Full Text] [Related]
5. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity.
Lauer TM; Agrawal NJ; Chennamsetty N; Egodage K; Helk B; Trout BL
J Pharm Sci; 2012 Jan; 101(1):102-15. PubMed ID: 21935950
[TBL] [Abstract][Full Text] [Related]
6. Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.
Gupta P; Makowski EK; Kumar S; Zhang Y; Scheer JM; Tessier PM
Mol Pharm; 2022 Mar; 19(3):775-787. PubMed ID: 35108018
[TBL] [Abstract][Full Text] [Related]
7. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues.
Kaleli NE; Karadag M; Kalyoncu S
Proteins; 2019 Jul; 87(7):607-618. PubMed ID: 30883916
[TBL] [Abstract][Full Text] [Related]
8. Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.
Martin KP; Grimaldi C; Grempler R; Hansel S; Kumar S
MAbs; 2023; 15(1):2191301. PubMed ID: 36998195
[TBL] [Abstract][Full Text] [Related]
9. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.
Douthwaite JA; Sridharan S; Huntington C; Hammersley J; Marwood R; Hakulinen JK; Ek M; Sjögren T; Rider D; Privezentzev C; Seaman JC; Cariuk P; Knights V; Young J; Wilkinson T; Sleeman M; Finch DK; Lowe DC; Vaughan TJ
MAbs; 2015; 7(1):152-66. PubMed ID: 25484051
[TBL] [Abstract][Full Text] [Related]
10. How can we discover developable antibody-based biotherapeutics?
Bauer J; Rajagopal N; Gupta P; Gupta P; Nixon AE; Kumar S
Front Mol Biosci; 2023; 10():1221626. PubMed ID: 37609373
[TBL] [Abstract][Full Text] [Related]
11. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.
Adachi M; Kurihara Y; Nojima H; Takeda-Shitaka M; Kamiya K; Umeyama H
Protein Sci; 2003 Oct; 12(10):2125-31. PubMed ID: 14500870
[TBL] [Abstract][Full Text] [Related]
12. In Silico Prediction of Diffusion Interaction Parameter (k
Tomar DS; Singh SK; Li L; Broulidakis MP; Kumar S
Pharm Res; 2018 Aug; 35(10):193. PubMed ID: 30128780
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
Thorsteinson N; Comeau SR; Kumar S
Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
[TBL] [Abstract][Full Text] [Related]
14. An adapted consensus protein design strategy for identifying globally optimal biotherapeutics.
Liu Y; Tsang K; Mays M; Hansen G; Chiecko J; Crames M; Wei Y; Zhou W; Fredrick C; Hu J; Liu D; Gebhard D; Huang ZF; Datar A; Kronkaitis A; Gueneva-Boucheva K; Seeliger D; Han F; Sen S; Kasturirangan S; Scheer JM; Nixon AE; Panavas T; Marlow MS; Kumar S
MAbs; 2022; 14(1):2073632. PubMed ID: 35613320
[TBL] [Abstract][Full Text] [Related]
15. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
[TBL] [Abstract][Full Text] [Related]
16. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling.
Park E; Izadi S
MAbs; 2024; 16(1):2362788. PubMed ID: 38853585
[No Abstract] [Full Text] [Related]
17. Developability assessment during the selection of novel therapeutic antibodies.
Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
[TBL] [Abstract][Full Text] [Related]
18. Models for Antibody Behavior in Hydrophobic Interaction Chromatography and in Self-Association.
Hebditch M; Roche A; Curtis RA; Warwicker J
J Pharm Sci; 2019 Apr; 108(4):1434-1441. PubMed ID: 30476509
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
20. Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody.
Campbell SM; DeBartolo J; Apgar JR; Mosyak L; McManus V; Beyer S; Bennett EM; Lambert M; Cunningham O
MAbs; 2021; 13(1):1883239. PubMed ID: 33557673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
